跳至主要内容
临床试验/NCT00369109
NCT00369109已完成不适用

Collection of Skin Biopsy With Hair Follicles as Surrogate to Develop Biomarker Assays From Patients With Advanced Solid Tumor Malignancies Receiving Either Single Agent Weekly Irinotecan or Gemcitabine

Barbara Ann Karmanos Cancer Institute2 个研究点 分布在 2 个国家目标入组 60 人开始时间: 2006年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
2
主要终点
Level of p-Chk1 and phospho-histone 2AX (p-H2AX) and possibly downstream pathway markers in hair follicles from skin biopsies of patients treated with gemcitabine hydrochloride or irinotecan hydrochloride for advanced solid tumors

研究概览

简要总结

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

PURPOSE: This laboratory study is collecting skin biopsy specimens from patients receiving irinotecan or gemcitabine for advanced solid tumors and using them to study change in DNA due to this treatment.

详细描述

OBJECTIVES:

Primary

  • Determine the level of p-Chk1 and phospho-histone 2AX (p-H2AX), an indicator of DNA damage, and possibly downstream pathway markers in hair follicles from skin biopsies of patients treated with gemcitabine hydrochloride or irinotecan hydrochloride for advanced solid tumors.

Secondary

  • Characterize the method for measurement (immunohistochemistry).
  • Measure inter- and intra-patient variability for the biomarker.
  • Partially characterize the dynamic time course of p-Chk1 and p-H2AX after administration of a DNA-damaging agent.

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Level of p-Chk1 and phospho-histone 2AX (p-H2AX) and possibly downstream pathway markers in hair follicles from skin biopsies of patients treated with gemcitabine hydrochloride or irinotecan hydrochloride for advanced solid tumors

次要结局

  • Characterization of the method for measurement (immunohistochemistry)
  • Dynamic time course of p-Chk1 and p-H2AX after administration of a DNA-damaging agent
  • Inter- and intra-patient variability for the biomarker

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验